US › Healthcare

Rallybio Corp (RLYB)

US · Healthcare · Biotechnology

$15.75+0.38%

Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Revenue

Revenue YoY

-100.0%

Net profit

$-2.7M

Profit YoY

-117.0%

EPS

$-0.48

Key statistics

Market cap

$85.4M

P/E

3.4

Forward P/E

0.0

P/B

0.91

Book value

$17.31

EPS (TTM)

$4.61

52-week high

$17.57

52-week low

$3.67

50-day MA

$16.71

200-day MA

$12.98

Beta

-0.77

Analyst view

with an average price target of $8.00.

Shareholding

Insiders

26.09%

Institutions

83.23%

Largest institutional holders

Fund	Stake
ADAR1 Capital Management LLC	17.44%
FMR Inc	14.96%
Viking Global Investors LP	9.87%
TPG GP A, LLC	7.13%
Nantahala Capital Management, LLC	7.09%
Pivotal bioVenture Partners Investment Advisor LLC	5.66%
Renaissance Technologies Corp	3.76%
Vanguard Capital Management, LLC	3.25%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Rallybio Corp — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.